Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report that the bioactivity of antcin H, an analog of the JAK2 inhibitor zhankuic acid A (ZAA), inhibits LMP1-induced JAK/STAT related signaling and induces lymphoma cell line apoptosis.
|
30277103 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results point to a second mechanism by which LMP1 dysregulates sumoylation processes and adds EBV-associated lymphomas to the list of malignancies associated with increased SUMO expression.
|
30659232 |
2019 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These data suggest new functions of the N terminus and transmembrane domains in LMP1 intra- and extracellular trafficking that are likely downstream of an interaction with CD63.<b>IMPORTANCE</b> EBV infection contributes to the development of cancers, such as nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin's disease, and posttransplant lymphomas, in immunocompromised or genetically susceptible individuals.
|
29950415 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
EBV, a human gamma herpesvirus that contributes to the progression of a multitude of lymphomas and carcinomas in immunocompromised or genetically susceptible populations, packages its major oncoprotein, LMP1, into vesicles for secretion.
|
29212935 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data further suggest that cytotoxic CD4 cells hold superior therapeutic value for LMP1 (EBV)-driven lymphomas.
|
29311309 |
2018 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epstein-Barr virus latent membrane protein 1 (LMP1) is expressed in multiple human malignancies, including nasopharyngeal carcinoma and Hodgkin and immunosuppression-associated lymphomas.
|
28835489 |
2017 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, the expression of either LMP1 or LMP2A may be sufficient to promote early-onset EBV-induced tumors in this model.<b>IMPORTANCE</b> EBV causes human lymphomas, but few models are available for dissecting how EBV causes lymphomas <i>in vivo</i> in the context of a host immune response.
|
28077657 |
2017 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, as many lymphomas only express subdominant EBV antigens that are less immunogenic, novel strategies are needed to manufacture EBV-specific T cell products specific for Latent Membrane Protein 1 (LMP1) and LMP2, which are expressed in lymphomas with type II and III latency.
|
27873282 |
2017 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and oncogenesis of other EBV-related malignancies, such as nasopharyngeal carcinoma and T/NK lymphoma.
|
26819314 |
2016 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression levels of LMP-1, LMP-2A, and LMP-2B and EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-LP were monitored by real-time quantitative-polymerase chain reaction (qRT-PCR) in cells from nine EBV-induced lymphomas and in matched lymphocytes from healthy subjects.
|
26548532 |
2016 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, EBV may contribute to the development and maintenance of human lymphomas even in the absence of LMP1.Here, we found that i.p. injection of human cord blood mononuclear cells infected with a LMP1-deficient EBV into immunodeficient mice induces B cell lymphomas.
|
25485679 |
2015 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that express them, we expanded LMP-cytotoxic T lymphocytes (CTLs) from patients with lymphoma using autologous dendritic cells and EBV-transformed B-lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17) or both LMP2 and ΔLMP1 (n = 33).
|
24344220 |
2014 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The oncogenic latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is involved in the pathogenesis of human nasopharyngeal carcinoma (NPC) and lymphoma.
|
23939952 |
2014 |
Lymphoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1.
|
24136166 |
2013 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.
|
22341446 |
2012 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomas in OKT3-treated animals (in contrast to lymphomas in the untreated animals) contained many LMP1-expressing cells.
|
22623780 |
2012 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a panel of transfected sublines of the B-lymphoma line BJAB expressing the viral genes associated with latent infection, we show that the EBV nuclear antigens, EBNA-1 and EBNA-3C, and the latent membrane protein 1, LMP-1, independently promote genomic instability, as detected by nonclonal chromosomal aberrations, DNA breaks and phosphorylation of histone H2AX.
|
19718051 |
2009 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the latent membrane protein-1 (LMP1) of the Epstein-Barr virus (EBV) is believed to be important for the transformation of germinal centre (GC) B cells, the precise contribution of this viral oncogene to lymphoma development is poorly understood.
|
18566961 |
2008 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The latency II program is limited to the expression of the nonimmunodominant antigens EBNA1, LMP1 and LMP2 and is seen in EBV-positive Hodgkin disease, nasopharyngeal carcinomas, and peripheral T/NK-cell lymphomas.
|
17471168 |
2007 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, these data suggest that immunotherapy targeting LMP1 in EBV-associated NK lymphomas and CAEBV might serve as an alternative treatment modality.
|
16479544 |
2006 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, IL-10 could induce the expression of LMP-1 in tonsillar B cells infected with the nontransforming, EBNA-2-deficient EBV strain P3HR1 and enhance LMP-1 expression in 2 EBV-positive NK lymphoma lines.
|
16332968 |
2006 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-kappaB c-Rel, was specifically activated.
|
16247482 |
2006 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EBV encodes several latent genes, among them latent membrane protein 1 (LMP1) and LMP2A, which are regularly expressed in EBV-positive Hodgkin lymphoma and posttransplantation lymphomas.
|
16076866 |
2005 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In all four patients, the lymphoma was associated with Epstein-Barr virus infection, detected by EBER in situ hybridization and the latency I phenotype as defined by lack of expression of LMP1.
|
15104301 |
2004 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study aims to investigate LMP-1 and TCRgamma gene status in upper aerodigestive tract lymphomas.
|
14989738 |
2004 |